Keratoconus is a progressive corneal disease in which the cornea weakens and begins to bulge outward into a cone-like shape. The bowing out of the cornea causes increased blurry and distorted vision. While specialty contact lenses, such as a scleral lens or the custom EyePrintPRO lens, can correct the vision, changes in prescription can occur frequently while the disease progresses. There is currently no cure for keratoconus, but there is a treatment available to stop the progression of the disease.
Corneal collagen crosslinking strengthens this corneal tissue to halt the progression of Keratoconus, Pellucid Degeneration, Corneal Ectasia. It was first developed in Europe at the University of Dresden in the late 1990s, and was fully approved for use in the EU in 2007. The United States began clinical trials in 2008. Dr. Christopher Ketcherside continues to offer our Cross-linking study to patients.
There are two approaches to treatment: epithelial-on and epithelial-off. The epithelial-on approach applies Riboflavin directly to the untouched cornea and then the eye is treated with UV light. In the epithelial-off procedure (used in our study), the eye is numbed and then the epithelium is removed to increase absorption and saturation of the Riboflavin into the cornea. After 30 minutes of Riboflavin drops to the treated eye(s), a UV light is applied for 5 minutes to activate the collagen formation.
You can read more about the Crosslinking procedure at the following websites:
If you are interested in becoming part of this study, please contact Mary Galloway at 913.322.9148.